Policy | October 25, 2021
India ramps up medical education with substantial investments
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
Second interchangeable biosimilar product approved by agency
The company claims that its Empagliflozin tablets are the most affordable in India
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
Equity raise to finance growth and investments in the biological space
Through this initiative, the Centre for Trauma will create curriculums and facilitate trauma-related courses for healthcare professionals at both urban and grassroot levels
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The company plans to expand its portfolio in regulated markets aggressively
Subscribe To Our Newsletter & Stay Updated
